Non-smooth plant disease models with economic thresholds
Related Experiment Video
Updated: May 18, 2026

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
Published on: July 3, 2020
Tingting Zhao1, Yanni Xiao, Robert J Smith
1Department of Applied Mathematics, Xi'an Jiaotong University, Xi'an 710049, People's Republic of China.
Abstract:
In order to control plant diseases and eventually maintain the number of infected plants below an economic threshold, a specific management strategy called the threshold policy is proposed, resulting in Filippov systems. These are a class of piecewise smooth systems of differential equations with a discontinuous right-hand side. The aim of this work is to investigate the global dynamic behavior including sliding dynamics of one Filippov plant disease model with cultural control strategy. We examine a Lotka-Volterra Filippov plant disease model with proportional planting rate, which is globally studied in terms of five types of equilibria. For one type of equilibrium, the global structure is discussed by the iterative equations for initial numbers of plants. For the other four types of equilibria, the bounded global attractor of each type is obtained by constructing appropriate Lyapunov functions. The ideas of constructing Lyapunov functions for Filippov systems, the methods of analyzing such systems and the main results presented here provide scientific support for completing control regimens on plant diseases in integrated disease management.
Related Concept Videos
Modeling with Differential Equations
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic Models: Overview
Microbe-Plant Interactions
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions